TACTICS OF PRENATAL CARE OF A YOUNG PATIENT WITH INHERITED LONG QT SYNDROME AND IMPLANTED CARDIOVERTER-DEFIBRILLATOR


Cite item

Full Text

Abstract

Ase report. This clinical case illustrates the example of prenatal care of a young woman with verified long QT syndrome (LQTS) type 2 with implanted cardioverter-defibrillator (ICD). In the course of pregnancy she had physiological sinus tachycardia, though the life-threatening ventricular arrhythmias and ICD shocks were not registered. On the 38th week of pregnancy the woman underwent the planned caesarean delivery (due to obstetrics indications) with live child. In the post-partum period she continued to experience recurrent VF episodes terminated after the adequate ICD shocks. Life-threatening arrhythmias were triggered by group PVC registered in the settings of persistent bradycardia. At the moment the number of the adequate ICD shocks reduced supported by betablocker therapy, the patient remains on continued standard monitoring. Discussion. Numerous cases of favourable course and even benefits in clinical and functional status during pregnancy in patients with LQTS are reported. This fact can be conditioned by the positive influence of physiological hemodynamical changes and hypersympathicotonia during pregnancy especially on the bradydependent arrhytmias. Conclusion. Pregnancy in patients with inherited LQTS and implanted ICDs is not always contraindicated and treatment tactics depends on certain clinical situation. Algorithms of pharmacological and shock therapy during pregnancy in women with ICD are corrected individually.

About the authors

R B Tatarsky

Almazov National Medical Research Centre

Email: fmrc@almazovcentre.ru
PhD, Leading Researcher, Electrophysiology Department, Almazov National Medical Research Centre, St. Petersburg.

V K Lebedeva

Almazov National Medical Research Centre

Email: fmrc@almazovcentre.ru
PhD, Senior Researcher, Electrophysiology Department, Almazov National Medical Research Centre, St. Petersburg.

T A Lubimtseva

Almazov National Medical Research Centre

Email: fmrc@almazovcentre.ru
PhD, Senior Researcher, Electrophysiology Department, Almazov National Medical Research Centre, St. Petersburg.

S V Gureev

Almazov National Medical Research Centre

Email: fmrc@almazovcentre.ru
PhD, Head of Electrophysiology Clinic, Almazov National Medical Research Centre, St.Petersburg.

D S Lebedev

Almazov National Medical Research Centre

Email: fmrc@almazovcentre.ru
PhD, Professor, Head of Electrophysiology Department, Almazov National Medical Research Centre, St.Petersburg.

S V Garkina

Almazov National Medical Research Centre

Email: svetlanagarkina@yahoo.com
PhD, Senior Researcher, Electrophysiology Department, Almazov National Medical Research Centre, St. Petersburg. Almazov National Medical Research Centre, 2 Akkuratova st., Saint-Petersburg, Russia, 197341

References

  1. ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). European Heart Journal. 2015;36(41):2793-2867. doi.org/10.1093/eurheartj/ehv316
  2. Schwartz PJ, Ackerman MJ. The long QT syndrome: a transatlantic clinical approach to diagnosis and therapy. Eur Heart J. 2013;34: 3109-3116.
  3. Mullally J, Goldenberg I, Moss AJ et al. Risk of life-threatening cardiac events among patients with long QT syndrome and multiple mutations. Heart Rhythm. 2013;10:378-382.
  4. Risgaard B, Waagstein K, Winkel BG et al. Sudden cardiac death. JACC Clin Electrophysiol. 2017;3:473-481.
  5. Seth R, Moss AJ, McNitt S et al. Long QT syndrome and pregnancy. J Am Coll Cardiol. 2007;49(10):1092-8. doi: 10.1016/j.jacc.2006.09.054
  6. Meregalli PG, Westendorp ICD, Tan HL et al. Pregnancy and the risk of torsades de pointes in congenital long-QT syndrome. Neth Heart J. 2008;16(12):422-425
  7. Ishibashi K, Aiba T, Kamiya C et al. Arrhythmia risk and в-blocker therapy in pregnant women with long QT syndrome. Heart. 2017;103(17):1374-1379. doi: 10.1136/heartjnl-2016-310617
  8. Schwartz PJ, Spazzolini C, Priori SG et al. Who are the long-QT syndrome patients who receive an implantable cardioverterdefibrillator and what happens to them? Data from the European Long-QT Syndrome Implantable Cardioverter-Defibrillator (LQTS ICD) Registry. Circulation 2010;122:1272-1282
  9. Earle N, Yeo Han D, Pilbrow A et al. Single nucleotide polymorphisms in arrhythmia genes modify the risk of cardiac events and sudden death in long QT syndrome. Heart Rhythm 2014;11:76-82
  10. ESC Guidelines for the management of cardiovascular diseases during pregnancy: The Task Force for the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). European Heart Journal. 2018;39(34):3165-3241. doi.org/10.1093/eurheartj/ehy340
  11. Wu J, Naiki N, Ding WG et al. A molecular mechanism for adrenergic-induced long QT syndrome. J Am Coll Cardiol. 2013; 63: 819-827.
  12. Kim JJ, Nemec J, Li Q et al. Synchronous systolic subcellular Ca2+- elevations underlie ventricular arrhythmia in drug-induced long QT type 2. Circ Arrhythm Electrophysiol. 2015;8:703-712.
  13. Steinberg C, Padfield GJ, Al-Sabeq B et al. Experience with bisoprolol in long-QT1 and long-QT2 syndrome. J Interv Card Electrophysiol. 2016;47(2):163-170. doi: 10.1007/s10840-016-0161-2
  14. Bennett MT, Gula LJ, Klein GJ et al. Effect of beta-blockers on QT dynamics in the long QT syndrome: measuring the benefit. Europace. 2014;16(12):1847-51. doi: 10.1093/europace/euu086

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2018 Tatarsky R.B., Lebedeva V.K., Lubimtseva T.A., Gureev S.V., Lebedev D.S., Garkina S.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).